Literature DB >> 22526485

Transcatheter renal artery embolization improves lung function in patients with autosomal dominant polycystic kidney disease on hemodialysis.

Shiho Yamakoshi1, Yoshifumi Ubara, Tatsuya Suwabe, Rikako Hiramatsu, Masayuki Yamanouchi, Noriko Hayami, Keiichi Sumida, Eiko Hasegawa, Junichi Hoshino, Naoki Sawa, Kennmei Takaichi, Masateru Kawabata.   

Abstract

BACKGROUND: Since 1996, transcatheter renal artery embolization (renal TAE) has been performed to reduce the volume of the kidneys in patients with autosomal dominant polycystic kidney disease (ADPKD) and complications of nephromegaly at our hospital. Respiratory dysfunction is often a serious problem in these patients before TAE. PATIENTS AND METHODS: Between January 2006 and October 2008, renal TAE was performed and lung function testing [percent vital capacity (%VC) and percent forced expiratory volume in 1 s (%FEV(1.0))] was done by spirometry in 28 patients on maintenance hemodialysis who had respiratory symptoms.
RESULTS: Renal volume was 6,330.5 ± 3,126.5 cm(3) (range 1,771-12,761 cm(3)) before TAE, and decreased significantly to 2,892.2 ± 1,841.7 cm(3) (range 622-6,961 cm(3)) by 12 months after TAE (p = 0.0001). The percent decrease of renal volume at 12 months after TAE versus baseline was 45.6 ± 14.6% (range 6.6-67.3%). %VC showed a significant increase from 95.9 ± 14.8% (range 63-127%) before renal TAE to 100.1 ± 11.7% (range 78-120%) at 12 months after TAE (p < 0.01). %FEV(1.0) was also significantly increased from 87.9 ± 15.0% (range 55-110%) before renal TAE to 92.5 ± 14.4% (range 58.0-115.0%) at 12 months after TAE (p < 0.01). The changes of VC (ΔVC%) and FEV(1.0) (ΔFEV(1.0)%) both showed a significant positive correlation with the reduction of renal volume (Δ renal volume) (p = 0.001 and p = 0.004, respectively).
CONCLUSION: Since TAE not only led to a significant decrease of renal volume in ADPKD patients with nephromegaly, but also improved lung function (both %VC and %FEV(1.0)), pulmonary dysfunction should be recognized as one of the extrarenal complications of ADPKD.

Entities:  

Mesh:

Year:  2012        PMID: 22526485     DOI: 10.1007/s10157-012-0619-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  9 in total

Review 1.  Polycystic kidney disease.

Authors:  Patricia D Wilson
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

3.  Postoperative spirometry after laparoscopy for lower abdominal or upper abdominal surgical procedures.

Authors:  J Joris; A Kaba; M Lamy
Journal:  Br J Anaesth       Date:  1997-10       Impact factor: 9.166

4.  New therapeutic option for autosomal dominant polycystic kidney disease patients with enlarged kidney and liver.

Authors:  Yoshifumi Ubara
Journal:  Ther Apher Dial       Date:  2006-08       Impact factor: 1.762

5.  Standardization of Spirometry, 1994 Update. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

6.  Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease on hemodialysis.

Authors:  Y Ubara; H Katori; T Tagami; S Tanaka; M Yokota; Y Matsushita; F Takemoto; T Imai; S Inoue; K Kuzuhara; S Hara; A Yamada
Journal:  Am J Kidney Dis       Date:  1999-11       Impact factor: 8.860

7.  Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients.

Authors:  Yoshifumi Ubara; Tetsuo Tagami; Naoki Sawa; Hideyuki Katori; Masafumi Yokota; Fumi Takemoto; Sumio Inoue; Keihachirou Kuzuhara; Shigeko Hara; Akira Yamada
Journal:  Am J Kidney Dis       Date:  2002-03       Impact factor: 8.860

Review 8.  Physiology of obesity and effects on lung function.

Authors:  Cheryl M Salome; Gregory G King; Norbert Berend
Journal:  J Appl Physiol (1985)       Date:  2009-10-29

9.  Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis.

Authors:  James A Driscoll; Sanjeev Bhalla; Helen Liapis; Aida Ibricevic; Steven L Brody
Journal:  Chest       Date:  2008-02-08       Impact factor: 9.410

  9 in total
  4 in total

1.  Impact of peritoneal dialysis on pulmonary function test in a patient with diaphragm paralysis.

Authors:  Marie-Christine Simard-Meilleur; Claude Poirier; Jean Ethier
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

2.  Sleep-Disordered Breathing in Patients with Polycystic Liver and Kidney Disease Referred for Transcatheter Arterial Embolization.

Authors:  Keiichi Sumida; Junichi Hoshino; Tatsuya Suwabe; Takatoshi Kasai; Noriko Hayami; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Naoki Sawa; Koji Narui; Kenmei Takaichi; Yoshifumi Ubara
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

Review 3.  Renal artery embolization-indications, technical approaches and outcomes.

Authors:  Arnaud Muller; Olivier Rouvière
Journal:  Nat Rev Nephrol       Date:  2014-12-23       Impact factor: 28.314

Review 4.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.